Yasheng pharmaceutical and Fuhong Hanlin reached cooperation on a new combination therapy

November 4, 2019 / Meitong news agency / -- a clinical research and development enterprise committed to developing innovative drugs in the treatment fields of tumor, hepatitis B and aging related diseases, AXA pharmaceutical announced on November 4 that it has reached strategic cooperation with Fuhong Hanlin, and will jointly explore the company's first approved product hanlikang (Li Kang) in the research of original innovative target Bcl-2 selective inhibitor apg-2575 and Fuhong Hanlin Combined treatment of chronic lymphoblastic leukemia (CLL) with tuximab injection promotes the cooperative research of clinical trials in China Apg-2575 is a new type of oral Bcl-2 selective inhibitor under the research of Yasheng pharmaceutical It can restore the programmed death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2, a member of Bcl-2 protein family, so as to kill the tumor and be used to treat a variety of blood malignancies In July 2019, the phase I clinical trial of apg-2575 for the treatment of hematological malignancies was launched in China, and the first case of drug administration has been completed The indications of this clinical study include chronic lymphocytic leukemia, non Hodgkin's lymphoma, etc Apg-2575 is the first domestic selective small molecule inhibitor of bcl-2 Before that, apg-2575 phase I clinical trial for the treatment of blood tumors has been launched in the United States and Australia It is worth mentioning that as of August 13, 2019, one CLL patient had a tumor volume reduction of more than 60%, reaching the standard of partial remission (PR); another three CLL patients received 400mg dose group, one of the key efficacy indicators of the three patients was peripheral blood absolute lymphocyte ALC reached CR standard in the first period of treatment So far, no tumor lysis syndrome (TLS) has been observed, which shows that the drug has good safety In addition, a number of preclinical research progress of apg-2575 was presented at this year's annual meeting of the American Association for cancer research (AACR), and showed its potential in combination medication Hanlikang ® is the first approved biological analogue in China, which is mainly used for the treatment of non Hodgkin's lymphoma In February 2019, hanlikang was officially approved by the State Food and Drug Administration for the listing of new drugs for 1) recurrent or drug-resistant central follicular lymphoma; 2) previously untreated stage III-IV follicular non Hodgkin's lymphoma; 3) treatment of CD20 positive diffuse large B cell non Hodgkin's lymphoma (DLBCL), i.e all indications of the original rituximab in China For a long time, rituximab combined with chemotherapy has been the standard treatment for NHL The listing of hanlikang ® has greatly enriched the treatment options for lymphoma patients, benefiting more than 1000 patients in the first month of listing It is of great significance for both sides to reach the agreement on cooperation of combined therapy Bcl-2 inhibitors have broad application prospects in the treatment of B-cell malignant tumor diseases, and their combination with rituximab will have positive significance in the treatment of chronic lymphocytic leukemia, and have the potential to expand to other B-cell malignant tumor indications Dr Yang Dajun, chairman of AXA pharmaceutical, said: "we are very pleased to reach this strategic cooperation with Fuhong Hanlin As the first domestic Bcl-2 selective small molecule inhibitor, apg-2575 is an important in-depth product line of Yasheng pharmaceutical cell apoptosis, which has great potential in the treatment of hematological malignancies Hanlikang ® is the first approved bio similar drug in China, which enriches the treatment options for lymphoma patients Combination therapy is the future trend AXA pharmaceutical will work closely with Fuhong Hanlin team to conduct in-depth research on the combination therapy of the two drugs We are looking forward to the potential synergistic effect of apg-2575 and hanlikang ® in the treatment of chronic lymphocytic leukemia, providing more treatment possibilities for Chinese patients " Dr Liu Shigao, co-founder, President and CEO of Fuhong Hanlin, said: "we are very happy to reach this strategic cooperation with AXA pharmaceutical Hanlikang ® is the first approved product of Fuhong Hanlin It has obtained all the indications approved by the original rituximab in China, providing more treatment options for lymphoma patients Apg-2575 is the original new type of oral Bcl-2 selective inhibitor, which is used as a single agent to treat a variety of blood malignant diseases, and also shows potential in the combination of drugs In the future, Fuhong Hanlin will work closely with Yasheng pharmaceutical to further promote the research of the combination therapy of the two drugs We expect hanlikang ® and apg-2575 to have a better synergistic effect on the indications of chronic lymphocytic leukemia, and provide more treatment options for Chinese patients " About Yasheng pharmaceutical, Yasheng pharmaceutical is an original new drug R & D enterprise based in China and facing the world It is committed to developing innovative drugs in the fields of cancer, hepatitis B and aging related diseases The company has a self-developed protein protein interaction target drug design platform Yasheng pharmaceutical R & D product pipeline mainly focuses on the inhibitors of key proteins of apoptosis pathway By inhibiting Bcl-2, IAP or MDM2-p53, it can restart the apoptosis process of tumor cells; the second and third generation inhibitors for kinase mutants in cancer treatment, etc The company now has 8 class 1 new drugs which have entered the stage of I / II clinical development in China, the United States and Australia On October 28, 2019, AXA pharmaceutical was successfully listed on the main board of the stock exchange of Hong Kong Limited About Fuhong Hanlin Fuhong Hanlin is a leading biopharmaceutical company in China It aims to provide innovative biopharmaceuticals with high quality and high price for patients all over the world Its products cover cancer, autoimmune diseases and other fields Since its establishment in 2010, the company has set up R & D centers in Shanghai, Taipei, China and California with the concept of global linkage, integration and innovation as its product development concept, which has the outstanding advantages of synergy Fuhong Hanlin's main product development strategy is the combination of imitation and creation Starting from the biological similar drugs, it gradually develops innovative monoclonal antibody products Combining with the self-developed anti-PD-1 and PD-L1 monoclonal antibodies, it is the first to launch immunotherapy in China It has prospectively arranged a diversified, innovative monoclonal antibody and tumor immunotherapy pipeline, and created a comprehensive production of research, development and commercial production The whole industry chain platform of physical medicine On September 25, 2019, Fuhong Hanlin was listed on the main board of the stock exchange of Hong Kong Limited 37